Upon completion of this program, participants will be able to :
- Understand when to use targeted therapy in patients suffering from lung cancer with EGFR mutations;
- Differentiate between the existing EGFR inhibitors in lung cancer treatments;
- Recognize osimertinib’s place in therapy for EGFR T790M mutation-positive lung cancer;
- Know the efficacy, the proper usage and safety of osimertinib;
- Counsel patients on the proper use of osimertinib and the management of possible side effects.